Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone44-12-2349-7415
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.14 million
Profitability
Miscellaneous
Employees61
Next Earnings DateN/A
OptionableNot Optionable
Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions
What is Bicycle Therapeutics' stock symbol?
Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."
How were Bicycle Therapeutics' earnings last quarter?
Bicycle Therapeutics Limited (NASDAQ:BCYC) posted its earnings results on Thursday, November, 7th. The company reported ($0.53) EPS for the quarter, beating the Zacks' consensus estimate of ($0.58) by $0.05. The firm had revenue of $0.61 million for the quarter, compared to the consensus estimate of $1 million. Bicycle Therapeutics had a negative net margin of 342.94% and a negative return on equity of 238.49%. View Bicycle Therapeutics' Earnings History.
What price target have analysts set for BCYC?
5 brokers have issued 12 month price objectives for Bicycle Therapeutics' stock. Their forecasts range from $14.00 to $22.00. On average, they expect Bicycle Therapeutics' stock price to reach $19.00 in the next year. This suggests a possible upside of 102.3% from the stock's current price. View Analyst Price Targets for Bicycle Therapeutics.
What is the consensus analysts' recommendation for Bicycle Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bicycle Therapeutics.
Has Bicycle Therapeutics been receiving favorable news coverage?
Press coverage about BCYC stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bicycle Therapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the company's share price in the near future. View News Stories for Bicycle Therapeutics.
Are investors shorting Bicycle Therapeutics?
Bicycle Therapeutics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 35,400 shares, an increase of 29.7% from the September 30th total of 27,300 shares. Based on an average daily volume of 20,900 shares, the short-interest ratio is presently 1.7 days. Currently, 0.3% of the shares of the company are short sold. View Bicycle Therapeutics' Current Options Chain.
Who are some of Bicycle Therapeutics' key competitors?
Some companies that are related to Bicycle Therapeutics include Collegium Pharmaceutical (COLL), Flexion Therapeutics (FLXN), Homology Medicines (FIXX), Emisphere Technologies (EMIS), Viking Therapeutics (VKTX), Akero Therapeutics (AKRO), DiaMedica Therapeutics (DMCAF), BioDelivery Sciences International (BDSI), Retrophin (RTRX), Advanz Pharma (CXRXF), Urogen Pharma (URGN), XBiotech (XBIT), Myovant Sciences (MYOV), Akorn (AKRX) and Kadmon (KDMN).
What other stocks do shareholders of Bicycle Therapeutics own?
Who are Bicycle Therapeutics' key executives?
Bicycle Therapeutics' management team includes the folowing people:
- Dr. Kevin Lee M.B.A., Ph.D., CEO & Director (Age 51)
- Mr. Lee H. Kalowski, Pres & CFO (Age 38)
- Mr. Christian Heinis, Scientific Founder
- Sir Gregory Winter, Co-Founder, Director & Member of Scientific Advisory Board (Age 68)
- Mr. Michael Skynner, Chief Operating Officer (Age 50)
When did Bicycle Therapeutics IPO?
(BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.
When does Bicycle Therapeutics' lock-up period expire?
Bicycle Therapeutics' lock-up period expires on Tuesday, November 19th. Bicycle Therapeutics had issued 4,333,333 shares in its IPO on May 23rd. The total size of the offering was $60,666,662 based on an initial share price of $14.00. After the end of Bicycle Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
How do I buy shares of Bicycle Therapeutics?
Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Bicycle Therapeutics' stock price today?
One share of BCYC stock can currently be purchased for approximately $9.39.
How big of a company is Bicycle Therapeutics?
What is Bicycle Therapeutics' official website?
How can I contact Bicycle Therapeutics?
Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 44-12-2349-7415.
MarketBeat Community Rating for Bicycle Therapeutics (NASDAQ BCYC)
MarketBeat's community ratings are surveys of what our community members think about Bicycle Therapeutics and other stocks. Vote "Outperform" if you believe BCYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
